Cost‐effectiveness analysis of sacral nerve stimulation as treatment for severe irritable bowel syndrome. (January 2016)

• Record Type: Journal Article
• Authors: Tipsmark, L. S.; Fassov, J.; Lundby, L.; Laurberg, S.; Ehlers, L.; Krogh, K.
• Is Part Of: Colorectal disease. Volume 18:Number 1(2016)
• Page Start: O30
• Page End: O36
• Publication Date: 2016-01
• Subjects: Cost‐utility analysis -- cost‐effectiveness -- sacral nerve stimulation -- irritable bowel syndrome; Colon (Anatomy) -- Diseases -- Periodicals; Rectum -- Diseases -- Periodicals; 616.34
• DOI: 10.1111/codi.13149
• Languages: English
• ISSNs: 1462-8910

Abstract

Abstract: Aim: Early results from sacral nerve stimulation (SNS) for severe irritable bowel syndrome (IBS) are promising but estimates of cost‐effectiveness are lacking. Our object was to perform a cost‐effectiveness analysis for SNS as an alternative to no treatment of IBS. Method: This retrospective analysis was based on the results from a randomized controlled crossover study with a cost‐utility analysis performed on patient‐level data and modelling of censored data over a projected period of time of up to 20 years. The analysis was conducted on an intention‐to‐treat approach. For estimation of the uncertainty of the incremental cost‐effectiveness ratio a bias corrected bootstrap analysis was performed. Results: Cost‐effectiveness was not reached for 4 years after permanent implantation (£31 270 per quality‐adjusted life years), which was the upper limit for patient follow‐up, but our data imply a cost‐effectiveness from a 7‐year perspective onwards. Conclusion: The study indicates the SNS treatment for IBS is cost effective from a 7‐year perspective onwards.